Bevacizumab for retinopathy of prematurity

New England Journal of Medicine

Volumn 364, Issue 24, 2011, Pages 2359-2362

  Good, William V ^a   Palmer, Earl A ^b  

^a SMITH KETTLEWELL EYE RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; TREATMENT OUTCOME; VALIDATION STUDY; VISION TEST; EPIDEMIOLOGY; METHODOLOGY; NEWBORN; NOTE; OUTCOME ASSESSMENT; PREMATURITY; RECURRENT DISEASE; STANDARD; ANGIOGENESIS; DRUG INDICATION; GESTATIONAL AGE; INFANT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE; DEVELOPING COUNTRY; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; LOW LEVEL LASER THERAPY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BIAS (EPIDEMIOLOGY); HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RESEARCH DESIGN; RETINOPATHY OF PREMATURITY; DEVELOPING COUNTRIES; INTRAVITREAL INJECTIONS; LASER THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959299653     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1103460     Document Type: Letter

References (4)

1. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
2. Reynolds JD. Bevacizumab for retinopathy of prematurity. N Engl J Med 2011;364:677-8.
3. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: three-month outcome. Arch Ophthalmol 1990;108:195-204.
4. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.